By binding to domain III of the extracellular domain of the epidermal growth factor receptor (EGFR), which is overexpressed on tumor cells, cetuximab competitively inhibits the binding of EGF and other ligands, preventing the dimerization of EGFR [1]. This evidence concerns the gene EGFR and neoplasm.